ABBV
Price
$193.28
Change
+$4.25 (+2.25%)
Updated
Aug 1, 11:20 AM (EDT)
Capitalization
322.43B
84 days until earnings call
MRK
Price
$78.58
Change
-$3.17 (-3.88%)
Updated
Aug 1, 11:25 AM (EDT)
Capitalization
331.75B
90 days until earnings call
Interact to see
Advertisement

ABBV vs MRK

Header iconABBV vs MRK Comparison
Open Charts ABBV vs MRKBanner chart's image
ABBVIE
Price$193.28
Change+$4.25 (+2.25%)
Volume$1.79K
Capitalization322.43B
Merck & Co
Price$78.58
Change-$3.17 (-3.88%)
Volume$34.09K
Capitalization331.75B
ABBV vs MRK Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. MRK commentary
Aug 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and MRK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 01, 2025
Stock price -- (ABBV: $189.02 vs. MRK: $78.12)
Brand notoriety: ABBV and MRK are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 179% vs. MRK: 132%
Market capitalization -- ABBV: $322.43B vs. MRK: $331.75B
ABBV [@Pharmaceuticals: Major] is valued at $322.43B. MRK’s [@Pharmaceuticals: Major] market capitalization is $331.75B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 3 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).

  • ABBV’s FA Score: 3 green, 2 red.
  • MRK’s FA Score: 2 green, 3 red.
According to our system of comparison, ABBV is a better buy in the long-term than MRK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 5 TA indicator(s) are bullish while MRK’s TA Score has 3 bullish TA indicator(s).

  • ABBV’s TA Score: 5 bullish, 4 bearish.
  • MRK’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than MRK.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -0.95% price change this week, while MRK (@Pharmaceuticals: Major) price change was -7.12% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.50%. For the same industry, the average monthly price growth was +5.84%, and the average quarterly price growth was +13.33%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

MRK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.50% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRK($332B) and ABBV($322B) have the same market capitalization . MRK has higher P/E ratio than ABBV: MRK (935.64) vs ABBV (66.46). ABBV YTD gains are higher at: 9.302 vs. MRK (-20.000). ABBV has higher annual earnings (EBITDA): 17.2B vs. MRK (6.91B). ABBV has more cash in the bank: 12.8B vs. MRK (7.09B). MRK has less debt than ABBV: MRK (35.1B) vs ABBV (59.4B). MRK has higher revenues than ABBV: MRK (60.1B) vs ABBV (54.3B).
ABBVMRKABBV / MRK
Capitalization322B332B97%
EBITDA17.2B6.91B249%
Gain YTD9.302-20.000-47%
P/E Ratio66.46935.647%
Revenue54.3B60.1B90%
Total Cash12.8B7.09B180%
Total Debt59.4B35.1B169%
FUNDAMENTALS RATINGS
ABBV vs MRK: Fundamental Ratings
ABBV
MRK
OUTLOOK RATING
1..100
6363
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
10
Undervalued
PROFIT vs RISK RATING
1..100
1379
SMR RATING
1..100
1424
PRICE GROWTH RATING
1..100
5461
P/E GROWTH RATING
1..100
1691
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRK's Valuation (10) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (85). This means that MRK’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (79). This means that ABBV’s stock grew significantly faster than MRK’s over the last 12 months.

ABBV's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as MRK (24). This means that ABBV’s stock grew similarly to MRK’s over the last 12 months.

ABBV's Price Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as MRK (61). This means that ABBV’s stock grew similarly to MRK’s over the last 12 months.

ABBV's P/E Growth Rating (16) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (91). This means that ABBV’s stock grew significantly faster than MRK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVMRK
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
56%
Bearish Trend 1 day ago
55%
Momentum
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
50%
MACD
ODDS (%)
Bearish Trend 1 day ago
49%
Bearish Trend 1 day ago
52%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
47%
Bearish Trend 1 day ago
50%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
45%
Advances
ODDS (%)
Bullish Trend 10 days ago
56%
Bullish Trend 8 days ago
48%
Declines
ODDS (%)
Bearish Trend 1 day ago
45%
Bearish Trend 1 day ago
51%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
40%
Bullish Trend 1 day ago
63%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
52%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HYG80.380.05
+0.06%
iShares iBoxx $ High Yield Corp Bd ETF
CPSN26.23-0.01
-0.04%
Calamos S&P 500 Structured Alt Protection ETF - November
DUSA46.10-0.14
-0.29%
Davis Select US Equity ETF
REIT25.97-0.38
-1.44%
ALPS Active REIT ETF
CVIE63.73-1.23
-1.89%
Calvert International Responsible ETF